BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 34073805)

  • 41. Investigation of High Molecular Weight Size Variant Formation in Antibody-Drug Conjugates: Microbial Transglutaminase-Mediated Crosslinking.
    Zhao Y; Kim S; Zheng X; Kim SH; Han A; Chen TH; Wang S; Zhong J; Qiu H; Li N
    J Pharm Sci; 2023 Oct; 112(10):2629-2636. PubMed ID: 37586591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding of Designed Bispecific Antibody Therapeutics.
    Villafuerte-Vega RC; Li HW; Slaney TR; Chennamsetty N; Chen G; Tao L; Ruotolo BT
    Anal Chem; 2023 May; 95(17):6962-6970. PubMed ID: 37067470
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Native-MS Analysis of Monoclonal Antibody Conjugates by Fourier Transform Ion Cyclotron Resonance Mass Spectrometry.
    Campuzano IDG; Netirojjanakul C; Nshanian M; Lippens JL; Kilgour DPA; Van Orden S; Loo JA
    Anal Chem; 2018 Jan; 90(1):745-751. PubMed ID: 29193956
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing.
    Lakayan D; Haselberg R; Gahoual R; Somsen GW; Kool J
    Anal Bioanal Chem; 2018 Dec; 410(30):7837-7848. PubMed ID: 30328504
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A size exclusion-reversed phase two dimensional-liquid chromatography methodology for stability and small molecule related species in antibody drug conjugates.
    Li Y; Gu C; Gruenhagen J; Zhang K; Yehl P; Chetwyn NP; Medley CD
    J Chromatogr A; 2015 May; 1393():81-8. PubMed ID: 25818558
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation.
    Matsuda Y; Leung M; Okuzumi T; Mendelsohn B
    Antibodies (Basel); 2020 May; 9(2):. PubMed ID: 32443479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation.
    Yoder NC; Bai C; Tavares D; Widdison WC; Whiteman KR; Wilhelm A; Wilhelm SD; McShea MA; Maloney EK; Ab O; Wang L; Jin S; Erickson HK; Keating TA; Lambert JM
    Mol Pharm; 2019 Sep; 16(9):3926-3937. PubMed ID: 31287952
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biophysical Properties and Heating-Induced Aggregation of Lysine-Conjugated Antibody-Drug Conjugates.
    Gandhi AV; Arlotta KJ; Chen HN; Owen SC; Carpenter JF
    J Pharm Sci; 2018 Jul; 107(7):1858-1869. PubMed ID: 29626535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Application of triple quadrupole mass spectrometry for the characterization of antibody-drug conjugates.
    Källsten M; Pijnappel M; Hartmann R; Lehmann F; Kovac L; Lind SB; Bergquist J
    Anal Bioanal Chem; 2019 May; 411(12):2569-2576. PubMed ID: 30848315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis.
    Cao M; De Mel N; Jiao Y; Howard J; Parthemore C; Korman S; Thompson C; Wendeler M; Liu D
    MAbs; 2019; 11(6):1064-1076. PubMed ID: 31198090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advances in the Development of Site-Specific Antibody-Drug Conjugation.
    Zhou Q; Kim J
    Anticancer Agents Med Chem; 2015; 15(7):828-36. PubMed ID: 25731178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate.
    Luo Q; Chung HH; Borths C; Janson M; Wen J; Joubert MK; Wypych J
    Anal Chem; 2016 Jan; 88(1):695-702. PubMed ID: 26629796
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The Characterization of Drug-to-Antibody Ratio and Isoforms of ADCs Using LC and MS Technologies].
    Iizuka R; Kotch F; Xu A; Porter T; Shion H; Birdsall R; Chen W
    Yakugaku Zasshi; 2017; 137(5):525-528. PubMed ID: 28458283
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mass spectrometric characterization of transglutaminase based site-specific antibody-drug conjugates.
    Farias SE; Strop P; Delaria K; Galindo Casas M; Dorywalska M; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2014 Feb; 25(2):240-50. PubMed ID: 24359082
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control.
    Tang Y; Tang F; Yang Y; Zhao L; Zhou H; Dong J; Huang W
    Sci Rep; 2017 Aug; 7(1):7763. PubMed ID: 28798339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
    Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
    Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future.
    Beck A; D'Atri V; Ehkirch A; Fekete S; Hernandez-Alba O; Gahoual R; Leize-Wagner E; François Y; Guillarme D; Cianférani S
    Expert Rev Proteomics; 2019 Apr; 16(4):337-362. PubMed ID: 30706723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Site-specific conjugation of native antibody.
    Sadiki A; Vaidya SR; Abdollahi M; Bhardwaj G; Dolan ME; Turna H; Arora V; Sanjeev A; Robinson TD; Koid A; Amin A; Zhou ZS
    Antib Ther; 2020 Dec; 3(4):271-284. PubMed ID: 33644685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.